Login
$CRDF
$0.91 +$0.18 (24.97%) Live

$CRDF 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms

27 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

Seasoned oncology executive brings extensive clinical development expertise and a track record of advancing innovative cancer therapies

22 Oct 2026 8-K: Submission of Matters to a Vote of Security Holders

On October 22, 2026, Cardiff Oncology, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). A total of 48,084,246 shares of common stock, constituting a quorum, were represented in person or by valid pro...

14 Sep 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

11 Aug 2026 8-K: Results of Operations and Financial Condition

Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC

16 Jul 2026 8-K: Entry into a Material Definitive Agreement; Other Events

This Securities Purchase Agreement (this “Agreement”) is dated as of July 14, 2026, between Cardiff Oncology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its ...

11 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2026, Cardiff Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 41,614,848 shares of common stock, constituting a quorum, were represented in person or by valid proxies ...

03 Jun 2026 8-K: Regulation FD Disclosure

June 3, 2026 Interim Results from the Randomized, Controlled Phase 2 CRDF-004 Trial Onvansertib + SoC Chemo/Bevacizumab in First-Line RAS-Mutated mCRC

29 May 2026 8-K: Entry into a Material Definitive Agreement

As previously disclosed, on May 19, 2026, Cardiff Oncology, Inc. (the “Company”) filed a lawsuit against Nerviano Medical Sciences S.r.l. (“NMS”) disputing NMS’s allegation that the Company materially breached the License Agreement dated...

19 May 2026 8-K: Other Events

On May 19, 2026, Cardiff Oncology, Inc. (the “Company”) filed a lawsuit against Nerviano Medical Sciences S.r.L (“NMS”) disputing NMS’s allegation that the Company materially breached its license agreement (Agreement) for onvansertib. Th...

14 May 2026 8-K: Results of Operations and Financial Condition

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

09 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive Officer

02 Apr 2026 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation

Previously on January 26, 2026, Cardiff Oncology, Inc. (the “Company”) disclosed that Dr. Mark Erlander, CEO and James Levine, CFO had stepped down from their respective roles at the Company as part of a strategic review. On March 27, 20...

25 Feb 2026 8-K: Regulation FD Disclosure

Forward-looking statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate...

24 Feb 2026 8-K: Completion of Acquisition or Disposition of Assets

Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:

27 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

06 Nov 2025 8-K: Results of Operations and Financial Condition

– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer –

29 Jul 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) –

26 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 26, 2025, Cardiff Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 38,649,891 shares of common stock, constituting a quorum, were represented in person or by valid proxies ...

17 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

This Employment Agreement (the “Agreement”) is made and entered into effective as of June 16, 2025 (the “Effective Date”), by and between Roger Sidhu (the “Executive”) and Cardiff Oncology, Inc., a Delaware corporation (the “Company”).

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support